Trial · NCT03352427
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
NCT03352427, Phase 2, Terminated, University of Michigan Rogel Cancer Center; results first posted 2022-10-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations. Trials, record NCT03352427. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03352427
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
- NCT number
- NCT03352427
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Conditions
- Glioma, High Grade Glioma, Pontine Tumors
- Interventions
- Dasatinib, Everolimus
- First posted
- 2017-11-24
- Last updated
- 2022-10-05
- Results first posted
- 2022-10-05
- Limitations and caveats
Trial enrollment was limited due to requirement for patient insurance coverage for all aspects of treatment. Due to limited sample size, full statistical analysis isn't possible. Descriptive results of this cohort compiled with data available from patients treated locally with a similar treatment plan is available in the following publication: Miklja et al, JCI, 2020 \[PMID: 32603316\].
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) | 8 months | Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions. |
| Primary | Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG) | 12 months | Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions. |
| Primary | Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma | 56 Days | The overall response assessment will take into account response in both target and non-target lesions, as well as the appearance of new lesions. Partial Response (PR) will be defined as ≥50% decrease in size of tumor in comparison to baseline measurements. Complete Response (CR) will be defined as the disappearance of all abnormal signal. This includes return to normal size of the brain stem for brain stem lesions. Reported as percentage of participants with partial or better response at 56 days. |
| Secondary | Overall Survival | 1 year | Percentage of patients alive at one year. |
| Secondary | Overall Survival | up to 17 months | Percentage of participants alive at 2 years. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) | 8 months | percentage of participants | NUMBER | |
| PRIMARY | Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG) | 12 months | percentage of participants | NUMBER | |
| PRIMARY | Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma | 56 Days | percentage of participants | NUMBER | |
| SECONDARY | Overall Survival | 1 year | percentage of participants | NUMBER | |
| SECONDARY | Overall Survival | up to 17 months | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) | Dasatinib+Everolimus | 0 | percentage of participants | ||
| Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG) | Dasatinib+Everolimus | 0 | percentage of participants | ||
| Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma | Dasatinib+Everolimus | 0 | percentage of participants | ||
| Overall Survival | Dasatinib+Everolimus | 0 | percentage of participants | ||
| Overall Survival | Dasatinib+Everolimus | 0 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib+Everolimus | 3 | |
| Overall Study | COMPLETED | Dasatinib+Everolimus | 3 | |
| Overall Study | NOT COMPLETED | Dasatinib+Everolimus | 0 |
Source ClinicalTrials.gov
Adverse events29
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Muscle weakness lower limb | Musculoskeletal and connective tissue disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Eye disorders | Eye disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Dysarthria | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Dasatinib+Everolimus | 2 | 3 | |
| other | Fatigue | General disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib+Everolimus | 3 | 3 | |
| other | Ataxia | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Seizure | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Facial nerve disorder | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Hiccups | Respiratory, thoracic and mediastinal disorders | Dasatinib+Everolimus | 1 | 3 |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib+Everolimus | 3 | 3 |
| Total, other adverse events | Dasatinib+Everolimus | 3 | 3 |
| Total, serious adverse events | Dasatinib+Everolimus | 1 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32603316 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03352427
GET https://conductscience.org/api/trials/v1/NCT03352427/events?page=2